(IN BRIEF) Takeda’s investigational oral TYK2 inhibitor zasocitinib has received FDA Priority Review for the treatment of adults with moderate-to-severe plaque psoriasis, with a PDUFA decision ...
(PRESS RELEASE) ESSEN, 14-Sep-2026 — / EuropaWire / — Brenntag, a global distributor of chemicals and ingredients, has successfully placed a €500 million bond in the European capital market, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results